Files

Download

Download Full Text (487 KB)

Keywords

HSP90 Inhibitor, synovial sarcoma, cancer

Abstract

Synovial sarcomas are rare muscle cancers that have very few targeted therapies. HSP90 is a protein upregulated in this form of cancer and many others. A screening of this cancer was done in vitro, using FDA-approved drugs, showing that HSP90 could be a promising treatment option. A novel HSP90 inhibitor was applied to human and mouse synovial sarcoma cell lines and was analyzed after receiving a drug treatment for HSP90.

Document Type

Poster

Publication Date

2024-03-21

Language

English

College

Life Sciences

Department

Cell Biology and Physiology

University Standing at Time of Publication

Senior

Targeting HSP90: A Novel Approach to Combat Synovial Sarcomas

Included in

Microbiology Commons

Share

COinS